Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated by Analysts at StockNews.com
Investment analysts at StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a report issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on ITCI. Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 target […]
Investment analysts at StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a report issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on ITCI. Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 target […]
